Table 2.

Serotonin (SERT) and dopamine (DAT) transporter binding potential (BP_ND) changes in patients with social anxiety disorder (SAD) after treatment with SSRI + ICBT or placebo + ICBT.

	x	y	z	Z	PFWE	Cluster volume1
Serotonin transporter (SERT)
SSRI + ICBT
Occupancy
All regions				Inf
Placebo + ICBT
Increase BPND
Raphe	−4	−30	−28	3.31	0.009	632
Dopamine (DAT)
SSRI + ICBT
Increase
L Amygdala	−28	4	−18	3.41	0.008	752
R Amygdala	18	0	−18	3.59	0.005	1432
L Hippocampus	−36	−18	−14	3.92	0.006	376
R Hippocampus	30	−28	−6	3.36	0.035	24
L NAcc	−12	12	−12	3.27	0.005	264
R NAcc	12	12	−12	3.09	0.007	168
L Putamen	−24	12	−10	3.44	0.026	328
Placebo + ICBT
Increase
L Amygdala	−24	4	−18	3.58	0.006	968
R Amygdala	20	6	−18	4.04	0.002	1440
L Hippocampus	−20	−20	−14	3.36	0.040	16
R Hippocampus	28	−16	−22	4.43	0.001	568
L NAcc	−12	10	−14	3.71	0.001	224
R NAcc	12	12	−12	3.04	0.009	56
L Putamen	−16	16	−10	3.28	0.046	16
R Putamen	30	12	−8	3.86	0.009	504

MNI Montreal Neurological Institute, L left, R right, NAcc Nucleus Accumbens.

^aCluster volume in mm³.